Page 104 - Sohini Das

Fortis Healthcare stake sale: Munjal-Burman seek level playing field

Hero Enterprise has criticised the Fortis Healthcare board's latest decision and has sought a level playing field for all the bidders

Rs 40-bn rights issue addresses concerns of Fortis shareholders: Ranjan Pai

Now there is also a plan to launch a Rs 40-billion rights issue for all shareholders after the demerger, which will help existing Fortis shareholders to participate, he added

Manipal sweetens offer for Fortis hospitals, proposes Rs 40-bn rights issue

Fortis Healthcare notified the stock exchange that it had received an unsolicited binding offer, which was under consideration

10 years of pharmaceutical sector: Controls, regulations stymie growth

It has also been a decade of major mergers and acquisitions, the most noteworthy one perhaps being the Sun Pharma-Ranbaxy deal

Olx betting on B2C segment to boost market share in used-car market

At present, OLX gets around 120,000 fresh unique B2C listing every month and 450,000 unique listings every month overall

Price crash ahead? Key diabetes, cancer drugs to go off-patent in India

The development is likely to trigger launch of generic versions by Indian drug majors; this would be a great relief to patients as prices might come down by 25% or so

How Eris is weaving a success story around its 4 distressed acquisitions

Eris Lifesciences started new neuro-psychiatry and women healthcare divisions for Strides portfolio and a new nutrition division for UTH portfolio

Danone's dairy tales: Why the French major gave up on India's market

Why did the French major give up on the world's largest dairy market and what does that mean for other brands in the fray?

GM raced ahead of peers, selling more vehicles as it exited India

In passenger cars, the firm even outpaced M&M by a huge margin; it has also consistently had a better market share than other foreign companies operating in India

Zydus Cadila sees 60% of topline from US by FY20 even as rivals lose share

Company has already received highest number of USFDA approvals since April 2017 and aims to launch 75% of these

Approval for generics drug up but US business shrinks for home firms

The trend is likely to continue for the next few quarters before the benefit from new drug launches start to accrue

Problem of plenty: Milk procurement hit, prices to dairy farmers drop 20%

A private dairy based in the NCR said the market was flush with SMP and prices had fallen to Rs 150 a kg or so in the domestic market, down by 30 per cent

What ails India's pharma sector? Brand launches last year lowest since 2013

In 2017, there were only 3,932 pharma brand launches, of which 386 were in the dermatology segment alone

Scooters are set to take over rural India and it's because of working women

Data reveal that in traditional agrarian states, the growth of scooters has come at the cost of motorcycle sales

Relief for used car players as GST rate slashed for second-hand vehicles

The abolition of the cess on ambulances was positive for Force Motors, the largest player in that segment, India Infoline added

MLA & Dalit activist Jignesh Mevani is force majeure for the marginalised

Taking pot shots at the prime minister is part and parcel of Mevani's reputation as a rising star in national politics

More USFDA approvals do not mean better margins for Indian 'big pharma'

Indian pharma firms including their subsidiaries have received around 304 abbreviated new drug application approvals from the USFDA in 2017

Now, a robotic arm to perform angioplasty in India for the first time

Ahmedabad-based Apex Heart Institute has brought vascular robotic tech from the US

Healthy trend: Indian pharma firms see rise in USFDA drug approvals in FY18

Ahmedabad-headquartered Cadila Healthcare has received the largest number of approvals, at 76, so far in FY18

GST woes: Come Uttarayan, fewer kites to flank Allahabad skies

GST woes plague the small time manufacturers who are struggling to comply; prices up 35%; production down 40%; shipments to other states down too